Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Kova

FuturHealth
Graded #215

Higher grade

vs+21.299999999999997
Kova
Graded #498

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 44.3/100.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +40
60
20
Dose & formulationFuturHealth +41
81
40
Clinical oversightKova +4
67
71
Labs & monitoringFuturHealth +9
61
52
FulfillmentFuturHealth +1
62
61
Contract termsFuturHealth +30
55
25
FuturHealth · left barKova · right bar

The numbers

MetricFuturHealthKova
WeighScore65.6/10044.3/100
GradeCC
Scorecard rank#215#498
Semaglutide$199/mo (compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Kova

Graded #498 · C

Strengths

  • Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
  • Medication is included in the plan price, with no separate pharmacy charge
  • States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
  • Companion app tracks weight, protein and side effects, with medication schedule reminders
  • You are not charged unless a provider approves treatment

Where it loses points

  • At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
  • The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
  • Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
  • Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
  • No pharmacy or prescribing medical group is named anywhere on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard